Alexander Mansour, MBA
Advertisement
Articles by Alexander Mansour, MBA
The Centers for Medicare and Medicaid Services finalized a ruling that slashes reimbursement rates on drugs that qualify under the 340B program.
Advertisement
Latest Updated Articles
- Opinion: CMS 340B Reimbursement Cuts Cause Big Pharma Profits While Underserved Patients Lose
Published: January 4th 2018 | Updated:
Opinion: CMS 340B Reimbursement Cuts Cause Big Pharma Profits While Underserved Patients LosePublished: January 3rd 2018 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Bepirovirsen Shows Breakthrough Potential for Functional Cure in Chronic Hepatitis B
2
FDA Grants National Priority Vouchers to Enlicitide Decanoate, Sacituzumab Tirumotecan
3
New Federal Dietary Guidelines Emphasize Protein and Real Foods While Cutting Sugar
4
Surveys Find Significant Gaps in Public’s Understanding of Shared Decision-Making on Vaccinations
5